Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

Background Antibodies blocking programmed death (PD)-1 or its ligand (PD-L1) have revolutionized cancer care, but many patients do not experience durable benefits. Novel treatments to stimulate antitumor immunity are needed in the PD-(L)1 refractory setting. The stimulator of interferon genes (STING...

Full description

Saved in:
Bibliographic Details
Main Authors: Shailender Bhatia, Paul Nghiem, Rima Kulikauskas, Candice Church, David M Koelle, Lisa Tachiki, Kimberly Smythe, Thomas Pulliam, Shira Tabachnick-Cherny, Saumya Jani, Peter H Goff, Rashmi Bhakuni, Brandon W Seaton
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/10/e009803.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/10/e009803.full

Similar Items